



AN2 Therapeutics to Participate at Upcoming Investor Conferences

February 20, 2025

MENLO PARK, Calif.--(BUSINESS WIRE)--Feb. 20, 2025-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that company management will participate in two upcoming investor conferences in March.

Details of the events are as follows:

TD Cowen 45th Annual Health Care Conference

- Eric Easom, Co-Founder, Chairman, President and CEO will provide a corporate overview on Monday, March 3, 2025 at 2:30 pm ET, and members of management will be available for 1X1 meetings.

Leerink Partners Global Healthcare Conference

- Members of management will be available for 1X1 meetings on Wednesday, March 12, 2025.

A webcast of the Cowen Health Care Conference presentation can be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com. An archived replay will be available for at least 30 days following the presentation.

About AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. AN2 has a pipeline of boron-based compounds in development for Chagas disease, NTM, and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. For more information, please visit our website at www.an2therapeutics.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20250220323899/en/): <https://www.businesswire.com/news/home/20250220323899/en/>

COMPANY CONTACT:

Lucy O. Day
Chief Financial Officer
l.day@an2therapeutics.com

INVESTOR AND MEDIA CONTACT:

Anne Bowdidge
ir@an2therapeutics.com

Source: AN2 Therapeutics, Inc.